Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
2010 · British Journal of Cancer · 179 citations
https://doi.org/10.1038/sj.bjc.6605507